R&D projects

Nucaps, within its business plan and activity, proposes a continuous commitment to new R&D projects; research and development projects and the technology transfer to market.

In collaboration with the most prestigious technology centers in Navarra and with food and pharmaceutical industries, Nucaps continues researching in order to improve the solutions offered by its technology for an effective and safe oral supply of bioactives and probiotics.

This project counts with the support of the Government of Navarra and the European Union.

Proteocaps

Microencapsulated Enzybiotics

Development of innovative microencapsulated products as effective and safe oral administration system of new enzybiotics (enzymes as an alternative to antibiotics to combat pathogenic bacterial infections) and that confer advanced functional and technological characteristics with a high impact in the fight against multidrug-resistant intestinal bacteria E. coli.

The bacterium “Escherichia coli” (E. coli) normally resides in the intestines of humans and animals, some E. coli are pathogenic, that is, they produce diseases, and are responsible for intestinal infections that cause diarrhea or urinary infections, being in some cases even fatal.

E. coli has become the first cause of nosocomial infection and the inadequate use of antibiotics in urinary infections has caused that E. coli has developed antimicrobial resistance.

Gastrointestinal infections are one of the most important causes of morbidity and mortality among infants and children. In Asia, Africa and Latin America, the probability that a child dies before age 5 for these causes can reach 50%.

Thus, the development of new alternative antimicrobial agents and new treatment approaches to eliminate resistant microorganisms and to minimize the appearance of new antibacterial resistance has become an urgent issue.

  • Title: PROTEOCAPS. Improvement of the bioavailability of enzymes that can be used as new antibiotics against intestinal human infections caused by Escherichia coli.
  • Identification Number: 0011-1365-2019-000140
  • Implementation period: April 2019-December 2020
  • Partners: NUCAPS Nanotechnology, S.L., IKAN Biotech S.L.

This project has been approved by the Government of Navarre in the R&D projects 2019 call and it is co-financed (50%) by the FEDER funds through the Programa Operativo 2014-2020 de Navarra.

This enterprise has received a 50% co-financed grant by the European Regional Development Fund through the Programa Operativo FEDER 2014-2020 de Navarra.

BioFood

Biotechnology for healthy food

The project proposes a research on microbial bioprocesses based on the role and behavior of the intestinal microbiota. Its objective is to obtain fermented foods and microencapsulated, probiotic, postbiotic and symbiotic ingredients (probiotics + prebiotics), with beneficial effects on the regulation of intestinal microbiota, obesity and the prevention of inflammatory processes. Some of the innovations of international scope proposed by the project are the microencapsulation of probiotics capable of overcoming the intestinal tract and being released in the areas with the greatest effect, the production of postbiotics, which would avoid the need to work with live microorganisms or the evaluation of the symbiotic effect of the combination of postbiotics with a prebiotic such as olive polyphenol

The main function of the intestinal microbiota is metabolic, degrading the undigested carbon and protein residues in the small intestine, giving rise to short chain fatty acids and others that modify the intestinal pH, favoring the absorption of trace elements. In addition, it contributes to regulate the metabolism of cholesterol and constitutes a contribution of extra energy to the body, while synthesizing vitamins and metabolizing toxic substances. In addition, the microbiota forms part of the intestinal barrier, preventing the nesting and penetration of pathogens, and modulates the immune system. It has, therefore, a great impact on our health. In fact, it has been observed that deviations from the normal state of the microbiota could be a cause, or at least a factor, of metabolic, immune or degenerative diseases.

Fermented foods and probiotics are gaining interest in recent years for their potential health benefit, most of them related to their influence on the gut microbiota. However, there are still important challenges to solve in order to develop and expand this type of products and favor their consumption.

On the other hand, microorganisms generate, fruit of their metabolism, elements that are of great functional interest: nutrients, postbiotics, bioactive compounds, etc,

The project aims to study and research microbiological bioprocesses both within the human body (those originated by the gut microbiota), and outside, in the fermentation of food or in bioreactors, in order to generate ingredients (probiotic and postbiotic) and foods that are beneficial to health and have a proven health effect

  • Title: Use of biotechnology to obtain healthy ingredients and food (BIOFOOD)
  • Identification Number: 0011-1411-2019-000008
  • Implementation period: July 2019-November 2021
  • Partners:NUCAPS NANOTECHNOLOGY S.L., BROTALIA S.L., INBIOLEV SL, GARUNKOOK S.L., BIOASAUN, S.A., CENTRO NACIONAL DE TECNOLOGÍA Y SEGURIDAD ALIMENTARIA (CNTA) y UNIVERSIDAD DE NAVARRA

This project has been approved by the Government of Navarre in the Strategic R&D projects 2019-2021 call and it is co-financed (50%) by the FEDER funds through the Programa Operativo 2014-2020 de Navarra.

This enterprise has received a 50% co-financed grant by the European Regional Development Fund through the Programa Operativo FEDER 2014-2020 de Navarra.

Nanoresveratrol

Enhancing the bioavailability of resveratrol by nanoencapsulation

Resveratrol (3,5,4-trihydroxystilbene) is a phytoalexin present in natural food products such as grapes, wine, peanuts, and berries with GRAS (Generally Recognised as Safe) regulatory status.

In the last years, several studies have demonstrated the potential health benefits of resveratrol. Some of these benefits are antioxidizing and anti-atherosclerosis effects, chemoprotective and cardiovascular protective effects and the capacity to inhibit platelet aggregation. However, resveratrol exhibits low stability, low water solubility and it is rapidly metabolized in vivo, which contributes to a limited cell absorption upon oral administration and therefore a very low bioavailability. Therefore, the therapeutically potential of resveratrol only will be achieve if the limitations tied to its low bioavailability are overcome.

In the last years, interest in nanotechnology has grown considerably, and researchers have investigated its use in increasing the clinical efficacy of natural products, such as resveratrol. Zein nanoparticles promote a 20-fold increase of resveratrol´s bioavailability in rats. Furthermore, the efficacy of this nanoparticles was proved in a mouse model of endotoxic shock. These nanoparticles were able to diminish the endotoxic symptoms induces by the ip administration of LPS.

In the light of these reports, Nucaps, in collaboration with Idifarma, is exploring the feasibility of the oral administration in humans of resveratrol-loaded zein nanoparticles. For this purpose, zein nanoparticles are being transfer from a laboratory scale to pilot and industrial scale and the hypothesis proved in rats, that these kind of nanocarriers can increase the bioavailability of resveratrol will be tested in humans.

  • Title: NANOCAPS
  • Identification Number: 0011-1365-2018-000285
  • Implementation period: February 2018-December 2019
  • Partners: NUCAPS Nanotechnology, S.L., IDIFARMA desarrollos farmacéuticos S.L.

This project has been approved by the Government of Navarre in the R&D projects 2018 call and it is co-financed (50%) by the FEDER funds through the Programa Operativo 2014-2020 de Navarra.

This enterprise has received a 50% co-financed grant by the European Regional Development Fund through the Programa Operativo FEDER 2014-2020 de Navarra.

Nanocaps

Looking for new encapsulation materials

Most nutraceutical products are intended for their oral administration. However, it remains a challenge as these substances usually present low stability within the gut and poor penetration properties directly related to their physico-chemical characteristics (e.g., molecular weight, MW, hydrophilicity, ionised groups, etc.). Moreover, in some cases they also show disgusting organoleptic characteristics.

To overcome these drawbacks and, then, promote the oral absorption and increase the bioavailability of the bioactive compounds, different strategies have been proposed. Among others, the nanoencapsulation in nanocarriers is a very promising strategy as it allows efficient loading of the nutraceuticals inside the carrier thereby protecting the cargo against degradation and promoting a controlled release, masking the odour and flavour of the active product.

In this context, food proteins such as casein, soya and zein fulfil the criteria for an ideal carrier (non-toxic, biocompatible, GRAS status…) among others such as resistance against digestive enzymes, bioadhesive capacities and hydrophobicity, which makes the preparation of colloidal structures easy.

In this context, the main objective of NanoCaps, a project in collaboration with CNTA and University of Navarra, is the design and development of new types of nanoparticles based on natural source materials.

Two strategies are being apply: on the one hand, the project works on the co-encapsulation, and surface decoration of Nucaps patented particles and, on the other hand, new materials for the encapsulation of bioactive compounds are being investigated.

  • Title: NANOCAPS
  • Identification Number: PT032-033 NanoCaps
  • Implementation period: February 2018-November 2019
  • Partners: Centro Nacional de Tecnología y Seguridad Alimentaria (CNTA), Universidad de Navarra (UNAV) y NUCAPS NANOTECHNOLOGY S.L.

This project has been approved by the Government of Navarre in the R&D projects 2018 call and it is co-financed (50%) by the FEDER funds through the Programa Operativo 2014-2020 de Navarra.

This project has received a 50% co-financed grant by the European Regional Development Fund through the Programa Operativo FEDER 2014-2020 de Navarra.

Biocaps

PROBIOTICS ENCAPSULATED IN VEGETABLE PROTEIN AND FREE OF ALLERGEN.

NUCAPS NANOTECHNOLOGY is going to develop innovative microencapsulates of probiotic bacteria based on the use of allergen-free vegetable proteins that give them advanced technological characteristics for food, nutricosmetic, and nutraceutical sectors.

This project has as a starting point the previous developments based on dietary proteins in the NANOCAPS, BIOFOOD, and INMUNOCAPS projects.

The project falls within the “Health” sector of the S3 smart specialization strategy, in the “Biotechnology” strategic technology, and responds to the challenge “Commitment to healthy eating”. This project will allow Nucaps, the first company in the world to encapsulate probiotics using natural proteins, to have new methods to encapsulate microorganisms, becoming an international benchmark.

  • Title: BIOCAPS, probiotics encapsulated in vegetable protein and free of allergens.
  • Execution Period: 2021 – 2023
  • Entity / s executing the project: NUCAPS NANOTECHNOLOGY.

Inmunocaps

ENHANCING THE VACCINAL IMMUNE RESPONSE THROUGH THE USE OF MICROENCAPSULATED PROBIOTICS

Co-encapsulation of probiotics and vaccines to create a new product for human and animal health. This product derives from the synergy between probiotics and vaccines.

Sometimes vaccines do not have a good effect, due to problems with intestinal bacteria, being especially critical in the first years of life. An imbalance in the intestinal flora can predispose the immune system to not respond efficiently to vaccines.

NUCAPS NANOTECHNOLOGY will investigate a solution in the design of microcapsules that contain the vaccine together with probiotics to help them have the proper effect.

MicroBiomics


Applications of the multi-omic study of the microbiota to the development of innovative biotechnological solutions in the health area.

μBiomics (microBiomics) proposes the design, development, and implementation of a multi-meta-omic strategy that allows characterizing, at a level of detail never done before and in a completely new way, the role of the microbiota in different pathological processes (digestive, autoimmune, oncological), as well as its contribution to the response, in terms of efficacy and safety, of patients to different clinical/therapeutic interventions. From an experimental point of view, microbiota samples of different origins, coming from patients, will be analyzed using a combination of meta-omic technologies. These techniques will generate a huge amount of data that will be integrated, not only at the omic level but with other clinical data, using bioinformatic tools.

The final objective of the project is to identify bacterial communities, and enzymatic activities associated with them, that may be useful for the design of biotechnology-based therapeutic strategies.

NUCAPS joins the main public and private hospitals and scientific research centers and teams in Navarra, using the most advanced technologies (nanotechnology, Big Data, Machine Learning and five omic technologies: 16S, metagenomics, metatranscriptomics, metaproteomics and metametabolomics) to generate and analyze close to a Petabyte of data to provide an effective response and create therapies based on the knowledge generated for diseases related to the microbiota in order to improve the health and quality of life of patients with these digestive and autoimmune diseases and oncology, which currently do not have adequate clinical solutions and treatments for their diseases.

It will contribute significantly to the intelligent specialization of Navarra in the area of ​​Biotechnology applied to health challenges.

  • Title: Applications of the multi-omic study of the microbiota to the development of innovative biotechnological solutions in the health area
  • Identification number: 2021.059
  • Execution Period: April 2021 – December 2023
  • Entity / s executing the project: Foundation for Applied Medical Research (FIMA), Clínica Universidad de Navarra (CUN), Complejo Hospitalario de Navarra (CHN), Fundación Miguel Servet (FMS), University of Navarra (CIMA LAB Diagnostics, Nutrition Research Center), ADITECH, NUCAPS and National Center for Food Technology and Safety (CNTA).

The project that has been approved by the Government of Navarra is an R&D project considered strategic and is part of the SIBERIA III Challenge. Innovative Solutions in Biotechnology for Energy, Health Challenges, Industry and Agri-food, having obtained the best technical score of all those presented.

Better Fish

The first plant-based fish fillet made of fermented food industry by-products and microalgae.

Participation in a European R&D project (Eurostars call) to develop the first vegetable-based fish fillet made from fermented by-products of the food industry and microalgae.

In addition to Nucaps, the company Better Nature from Uk, the Institute specialized in fermented foods (Center of Food and Fermentation Technologies- TFTAK) from Latvia and the Spanish company Neoalgae participate in this project.

With a duration of 3 years, a total budget of more than 1.6 million euros has been allocated.

  • Title: THE FIRST PLANT-BASED FISH FILET MADE FROM FERMENTED BY-PRODUCTS FROM THE FOOD INDUSTRY AND MICROALGAE.
  • Identification Number: CIIP-20212020
  • Execution Period: 3 years
  • Partners: NUCAPS Nanotechnology, S.L., Better Nature, TFTAK & Neoalgae.